Ignite Creation Date:
2025-12-25 @ 4:31 AM
Ignite Modification Date:
2026-02-03 @ 8:29 AM
Study NCT ID:
NCT00567918
Status:
COMPLETED
Last Update Posted:
2008-04-04
First Post:
2007-12-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
Sponsor:
Astellas Pharma Inc
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
FJ-506D-AC10
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Director
Old Organization:
Astellas Pharma Inc.